טוען...
Preclinical Development of PQR514, a Highly Potent PI3K Inhibitor Bearing a Difluoromethyl–Pyrimidine Moiety
[Image: see text] The phosphoinositide 3-kinase (PI3K)/mechanistic target of rapamycin (mTOR) pathway is a critical regulator of cell growth and is frequently hyperactivated in cancer. Therefore, PI3K inhibitors represent a valuable asset in cancer therapy. Herein we have developed a novel anticance...
שמור ב:
| הוצא לאור ב: | ACS Med Chem Lett |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
American Chemical
Society
2019
|
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6792169/ https://ncbi.nlm.nih.gov/pubmed/31620236 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acsmedchemlett.9b00333 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|